Our top pick for
Building a portfolio
ClearPoint Neuro, Inc is a medical devices business based in the US. ClearPoint Neuro shares (CLPT) are listed on the NYSE and all prices are listed in US Dollars. ClearPoint Neuro employs 67 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$2.90 - $31.29|
|50-day moving average||$20.59|
|200-day moving average||$15.62|
|Wall St. target price||$35.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.42|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$12.8 million|
|Gross profit TTM||$9.1 million|
|Return on assets TTM||-18.76%|
|Return on equity TTM||-194.8%|
|Market capitalisation||$352.3 million|
TTM: trailing 12 months
There are currently 324,892 ClearPoint Neuro shares held short by investors – that's known as ClearPoint Neuro's "short interest". This figure is 3.6% up from 313,583 last month.
There are a few different ways that this level of interest in shorting ClearPoint Neuro shares can be evaluated.
ClearPoint Neuro's "short interest ratio" (SIR) is the quantity of ClearPoint Neuro shares currently shorted divided by the average quantity of ClearPoint Neuro shares traded daily (recently around 569985.96491228). ClearPoint Neuro's SIR currently stands at 0.57. In other words for every 100,000 ClearPoint Neuro shares traded daily on the market, roughly 570 shares are currently held short.
However ClearPoint Neuro's short interest can also be evaluated against the total number of ClearPoint Neuro shares, or, against the total number of tradable ClearPoint Neuro shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ClearPoint Neuro's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ClearPoint Neuro shares in existence, roughly 20 shares are currently held short) or 0.0172% of the tradable shares (for every 100,000 tradable ClearPoint Neuro shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ClearPoint Neuro.
Find out more about how you can short ClearPoint Neuro stock.
We're not expecting ClearPoint Neuro to pay a dividend over the next 12 months.
ClearPoint Neuro's shares were split on a 1:40 basis on 26 July 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ClearPoint Neuro shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ClearPoint Neuro shares which in turn could have impacted ClearPoint Neuro's share price.
Over the last 12 months, ClearPoint Neuro's shares have ranged in value from as little as $2.9 up to $31.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ClearPoint Neuro's is 1.0353. This would suggest that ClearPoint Neuro's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N. V.
Steps to owning and managing TREB-U, with 24-hour and historical pricing before you buy.
Steps to owning and managing TIG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDAC, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB-WS, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TACT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TROX, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.